MétaCan
Menu
Back to cohort
Record W1972392271 · doi:10.1111/tri.12161

A cautionary tale of BK virus

2013· letter· en· W1972392271 on OpenAlexaff
Matthew J. Gillespie, Sarah E. Yost, Edward A. Meister, Bruce Kaplan

Bibliographic record

VenueTransplant International · 2013
Typeletter
Languageen
FieldMedicine
TopicPolyomavirus and related diseases
Canadian institutionsUniversity of Alberta
Fundersnot available
KeywordsBK virusImmunosuppressionMedicineViremiaImmunologyPolyomavirus InfectionsPopulationKidney transplantationTransplantationAntibodyInternal medicine

Abstract

fetched live from OpenAlex

Solid organ transplant recipients require lifelong immunosuppressive therapy to prevent rejection of their graft. However, this relatively nonspecific immunosuppression leaves the patient vulnerable to viral infections. BK virus (BKV) has become a common infection, which can lead to an inflammatory process in the kidney and may lead to graft loss. At this point in time, the only treatment for BKV is the reduction in immunosuppression. BKV is estimated to have a seroprevalence rate of around 75% in the adult population worldwide, while potentially exceeding 90% 1, 2. In most cases, the virus remains latent in urinary epithelium and poses no threat to the individual 3. However, if a patient develops BK viremia, most transplant centers reduce immunosuppression to prevent occurrence of frank nephropathy. Some investigators have posted that BK viremia may in fact serve as a crude marker of T cell immune competence 4. Given this, it is quite possible that complete resolution of viremia may increase vulnerability to alloimmune responses. As the development of donor-specific HLA antibodies has been shown to be a major cause of graft loss, the question of whether the decrease in immunosuppression obligated to eradicate BKV may lead to an increased risk of donor-specific antibodies (DSA). Our center retrospectively reviewed 248 charts of kidney and kidney–pancreas transplant recipients to observe the incidence of BKV, and of the patients who developed BKV, which ones developed DSA. The incidence of BK viremia at our center was found to be 14.1% (n = 35). All patients were treated with cessation of their anti metabolite and kept on dual therapy of tacrolimus and prednisone, with tacrolimus trough levels targeted at 4–8 ng/ml. Upon review of the patients with BK viremia, three patients developed de novo DSA with a BK viral load of less than 2000 copies that we will define as not persistent BK viremia. De novo DSA was not found in patients with persistent BK viremia of more than 2000 copies. No patients had pretransplant DSA and all developed DSA only after the BK viral load fell to less than 2000 copies; thus, 3 of 35 patients developed DSA within a year period. The incidence of de novo DSA in negative BK patients is 16 of 213 patients (7.5%). The number of patients in our study is not large, but it does support the concept that BKV may indeed be a biomarker for immune suppression. However, it also underscores the need for constant vigilance in this delicate balance. It may be possible that eradication of virus may not be ideal, but rather low levels may be a more appropriate goal. In any case, these cases offer a cautionary message regarding the need to study this issue in powered and randomized studies. The authors have declared no conflicts of interest. None.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.164
Threshold uncertainty score0.995

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.252
Teacher spread0.238 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueTransplant InternationalSame topicPolyomavirus and related diseasesFrench-language works237,207